ArticleToxins2026
Indole-3-Acetic Acid as a Putative Selective AhR Modulator Counteracts Skatole-Induced Dual-Hit Toxicity in Colorectal Cancer Cells.
Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Context-dependent functions of the aryl hydrocarbon receptor in gastrointestinal cancers: from microenvironmental regulation to precision targeted therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The rising incidence of colorectal cancer (CRC) in modernized societies is linked to diet-induced dysbiosis, characterized by a critical metabolic divergence: the depletion of protective indole-3-acetic acid (IAA) concurrent with the accumulation of toxic skatole (3-methylindole). However, the molecular mechanisms by which high concentrations of skatole drive malignancy-and whether IAA can counteract this toxicity-remain elusive. Here, we demonstrate that physiologically relevant concentrations of skatole (500 µM) significantly promote the proliferation of HCT-116 CRC cells through a "dual-hit" mechanism involving both aryl hydrocarbon receptor (AhR)-dependent genomic activity and AhR-independent activation of the ERK MAPK pathway. Notably, co-treatment with IAA (250 µM) effectively abrogated skatole-induced proliferation, restoring cell growth to baseline levels while sparing upstream MAPK phosphorylation. Mechanistic analysis indicates that IAA acts not merely as a competitor, but as a functional antagonist. Specifically, our findings suggest that IAA functions as a putative selective AhR modulator (SAhRM) that qualitatively reprograms AhR signaling. This modulation uncouples upstream MAPK phosphorylation from downstream cell cycle progression, effectively impeding the proliferative program even in the presence of skatole-induced stress. Furthermore, we propose a theoretical model of counter-balancing metabolic activation, hypothesizing that the oxidative environment associated with skatole metabolism may trigger the bioactivation of IAA into highly active anti-tumor derivatives. These findings suggest that restoring the gut IAA/skatole balance-either by targeting the bacterial enzyme indoleacetate decarboxylase (IAD) or via dietary resistant starch-may offer a promising precision nutrition strategy for CRC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.